Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Pacific Growth Keeps Regeneration at Overweight

Pacific Growth reiterates its overweight rating for Regeneration Technologies (RTIX).

Analyst Kate Sharadin tells S&P MarketScope that Regeneration Technologies is her top pick for medical technology stocks to own going into 2005. She expects several catalysts for 2005, including new products, new distribution, and supportive clinical data.

She believes Regeneration is undervalued vs. its peers, trading recently at only 19 times her 2005 earnings-per-share estimate, vs. 30 times for its peers.

Sharadin remains enthusiastic about the company's business and stock, yet trims her 44 cents 2005 earnings-per-share estimate to 40 cents on the view that 44 cents is too high, and the fact that the company will be sharing some future product revenues with Stryker Corp. (SYK), its distribution partner. She views $12 as fair value for the stock.

blog comments powered by Disqus